Advances in Relapsed/Refractory Myeloma: Keeping Pace With a Rapidly Evolving Treatment Landscape

This online program is based on a live satellite symposium covering the latest therapeutic strategies for the management of relapsed/refractory multiple myeloma including the latest clinical data on the safety and efficacy of emerging agents. Watch the on-demand webcast download the slidesets from the satellite symposium and read an expert commentary.

Share

Program Content

Activities

RR MM 2022 Downloadable Slides 1
Current Treatment Options at First Relapse in Relapsed/Refractory Myeloma
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 07, 2022

Expires: June 06, 2023

RR MM 2022 Downloadable Slides 2
Relapsed/Refractory Multiple Myeloma: Subsequent Therapy and Beyond
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 07, 2022

Expires: June 06, 2023

RR MM 2022 Downloadable Slides 3
CAR T Cells and Investigational Bispecific Antibodies in MM
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 07, 2022

Expires: June 06, 2023

No activities added yet

Activities

Advances in R/R MM
Experts Answer Pressing Questions on Recent Advances in Treatment of Relapsed/Refractory Multiple Myeloma
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: August 18, 2022

Expires: August 17, 2023

Faculty

cover img faculity

Natalie S. Callander, MD

Professor of Medicine
School of Medicine and Public Health
University of Wisconsin
Director, Myeloma Clinical Program
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin

cover img faculity

Noopur Raje, MD

Director, Center for Multiple Myeloma
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

cover img faculity

Paul G. Richardson, MD

Associate Professor of Medicine
Harvard Medical School
Clinical Director
Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute
Boston, Massachusetts

Provided by

ProCE Banner

Supporters

Supported by educational grants from

AbbVie Inc.

GlaxoSmithKline

Janssen administered by Scientific Affairs

Karyopharm Therapeutics

Regeneron Pharmaceuticals, Inc.